Literature DB >> 26315760

Alzheimer's Disease: Genomics and Beyond.

Fuhai Song1, Guangchun Han2, Zhouxian Bai1, Xing Peng1, Jiajia Wang1, Hongxing Lei3.   

Abstract

Alzheimer's disease (AD) is a major form of senile dementia. Despite the critical roles of Aβ and tau in AD pathology, drugs targeting Aβ or tau have so far reached limited success. The advent of genomic technologies has made it possible to gain a more complete picture regarding the molecular network underlying the disease progression which may lead to discoveries of novel treatment targets. In this review, we will discuss recent progresses in AD research focusing on genome, transcriptome, epigenome, and related subjects. Advancements have been made in the finding of novel genetic risk factors, new hypothesis for disease mechanism, candidate biomarkers for early diagnosis, and potential drug targets. As an integration effort, we have curated relevant data in a database named AlzBase.
© 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Brain transcriptome; Epigenome profiling; Genome-wide association study; Whole-exome sequencing

Mesh:

Year:  2015        PMID: 26315760     DOI: 10.1016/bs.irn.2015.05.001

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  2 in total

1.  MCKAT: a multi-dimensional copy number variant kernel association test.

Authors:  Nastaran Maus Esfahani; Daniel Catchpoole; Javed Khan; Paul J Kennedy
Journal:  BMC Bioinformatics       Date:  2021-12-11       Impact factor: 3.169

2.  A strategy to find novel candidate anti-Alzheimer's disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants.

Authors:  Bi-Wen Chen; Wen-Xing Li; Guang-Hui Wang; Gong-Hua Li; Jia-Qian Liu; Jun-Juan Zheng; Qian Wang; Hui-Juan Li; Shao-Xing Dai; Jing-Fei Huang
Journal:  PeerJ       Date:  2018-05-11       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.